{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:44:52Z","timestamp":1784907892780,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Regardless of line of therapy, treatment goals in chronic phase chronic myeloid leukemia (CML) are: avoid progression to accelerated phase or blast crisis CML such that patients achieve a life expectancy comparable with that of the general population; avoid adverse events (AEs); and restore and maintain quality of life. The most important prognostic factor for achieving these goals is response to tyrosine kinase inhibitors (TKIs) at key milestones. For patients failing a TKI, a treatment change is mandatory to limit the risk of progression and death. There is currently no precise guideline for patients that fail a second-generation TKI, and there is a paucity of data to guide clinical decision making in this setting. There is, therefore, an unmet need for practical and actionable guidance on how to manage patients who fail a second-generation TKI. Although the term \u2018failure\u2019 includes patients failing for resistance or intolerance, the focus of this paper is failure of a second-generation TKI because of resistance. CML patients who fail their first second-generation TKI for true resistance need a more potent therapy. In these patients, the key issues to consider are the relative appropriateness of early allogeneic hematopoietic stem cell transplantation or the use of a further TKI. Selection of the next line of treatment after second-generation TKI resistance should be individualized and must be based on patient-specific factors including cytogenetics, mutation profile, comorbidities, age, previous history of AEs with prior TKI therapy, and risk profile for AEs on specific TKIs. This expert opinion paper is not in conflict with existing recommendations, but instead represents an evolution of previous notions, based on new data, insights, and clinical experience. We review the treatment options for patients resistant to second-generation TKI therapy and provide our clinical opinions and guidance on key considerations for treatment decision making.<\/jats:p>","DOI":"10.1038\/s41375-020-0842-9","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T17:04:26Z","timestamp":1588611866000},"page":"1495-1502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Expert opinion\u2014management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors"],"prefix":"10.1038","volume":"34","author":[{"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"R\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol."},{"key":"842_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia."},{"key":"842_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med."},{"key":"842_CR4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ajh.24887","volume":"92","author":"SL Goldberg","year":"2017","unstructured":"Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017;92:1214\u201323.","journal-title":"Am J Hematol."},{"key":"842_CR5","first-page":"302","volume":"15","author":"SG Lee","year":"2017","unstructured":"Lee SG, Lipton JH. Everything old is new again: the case for imatinib as frontline therapy in 2017. Clin Adv Hematol Oncol. 2017;15:302\u20135.","journal-title":"Clin Adv Hematol Oncol."},{"key":"842_CR6","first-page":"302","volume":"15","author":"C Fava","year":"2017","unstructured":"Fava C, Saglio G. The biology of CML supports second-generation TKIs as frontline treatment. Clin Adv Hematol Oncol. 2017;15:302\u20137.","journal-title":"Clin Adv Hematol Oncol."},{"issue":"Suppl 2","key":"842_CR7","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94(Suppl 2):S141\u20137.","journal-title":"Ann Hematol."},{"key":"842_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","volume":"59","author":"G Saglio","year":"2018","unstructured":"Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma. 2018;59:1523\u201338.","journal-title":"Leuk Lymphoma."},{"key":"842_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajh.24249","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E. Chronic myeloid leukemia: first-line drug of choice. Am J Hematol. 2016;91:59\u201366.","journal-title":"Am J Hematol."},{"key":"842_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ajh.24247","volume":"91","author":"C Gambacorti-Passerini","year":"2016","unstructured":"Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Chronic myeloid leukemia: second-line drugs of choice. Am J Hematol. 2016;91:67\u201375.","journal-title":"Am J Hematol."},{"key":"842_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107\u201312.","journal-title":"Leukemia."},{"key":"842_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"NP Shah","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91:869\u201374.","journal-title":"Am J Hematol."},{"key":"842_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321\u201331.","journal-title":"Leukemia."},{"key":"842_CR14","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen J, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41\u201351.","journal-title":"Ann Oncol."},{"key":"842_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"842_CR16","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15:7519\u201327.","journal-title":"Clin Cancer Res."},{"key":"842_CR17","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242\u20139.","journal-title":"Blood."},{"key":"842_CR18","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, et al. Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012;87:E125\u20138.","journal-title":"Am J Hematol."},{"key":"842_CR19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1634\/theoncologist.2015-0337","volume":"21","author":"S Soverini","year":"2016","unstructured":"Soverini S, De Benedittis C, Mancini M, Martinelli G. Best practices in chronic myeloid leukemia monitoring and management. Oncologist. 2016;21:626\u201333.","journal-title":"Oncologist."},{"key":"842_CR20","doi-asserted-by":"publisher","first-page":"21982","DOI":"10.18632\/oncotarget.8010","volume":"7","author":"S Soverini","year":"2016","unstructured":"Soverini S, De Benedittis C, Polakova KM, Linhartova J, Castagnetti F, Gugliotta G, et al. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget. 2016;7:21982\u201390.","journal-title":"Oncotarget."},{"key":"842_CR21","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1182\/bloodadvances.2018021899","volume":"2","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, et al. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018;2:2254\u201361.","journal-title":"Blood Adv."},{"key":"842_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O\u2019Brien S, Ravandi F, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112:516\u20138.","journal-title":"Blood."},{"key":"842_CR23","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O\u2019Brien S, Quintas-Cardama A, Faderl S, Estrov Z, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009;114:4361\u20138.","journal-title":"Blood."},{"key":"842_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.6061\/clinics\/2015(08)04","volume":"70","author":"BF Ribeiro","year":"2015","unstructured":"Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, et al. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors\u2014a single center experience. Clinics. 2015;70:550\u20135.","journal-title":"Clinics"},{"key":"842_CR25","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1182\/blood.V126.23.4051.4051","volume":"126","author":"E Lomaia","year":"2015","unstructured":"Lomaia E, Zaritskey A, Shuvaev V, Martynkevich I, Fominykh M, Ovsyannikova E, et al. Efficacy of tyrosine kinase inhibitors in third line therapy in chronic phase chronic myeloid leukemia. Blood. 2015;126:4051.","journal-title":"Blood."},{"key":"842_CR26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2010.110","volume":"24","author":"FJ Giles","year":"2010","unstructured":"Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010;24:1299\u2013301.","journal-title":"Leukemia."},{"key":"842_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clml.2011.06.009","volume":"11","author":"J Cortes","year":"2011","unstructured":"Cortes J, Quintas-Cardama A, Jabbour E, O\u2019Brien S, Verstovsek S, Borthakur G, et al. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011;11:421\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"842_CR28","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","volume":"116","author":"AR Ibrahim","year":"2010","unstructured":"Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116:5497\u2013500.","journal-title":"Blood."},{"key":"842_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000562988.91652.94","volume-title":"Primary results of the phase 4 BYOND study of bosutinib for pretreated chronic phase chronic myeloid leukemia","author":"A Hochhaus","year":"2019","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Br\u00fcmmendorf TH, Smith BD, et al. Primary results of the phase 4 BYOND study of bosutinib for pretreated chronic phase chronic myeloid leukemia. Amsterdam: European Hematology Association; 2019."},{"key":"842_CR30","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/ajh.24536","volume":"91","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib. Am J Hematol. 2016;91:1206\u201314.","journal-title":"Am J Hematol."},{"key":"842_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00277-018-3507-2","volume":"98","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, et al. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Ann Hematol. 2019;98:321\u201330.","journal-title":"Ann Hematol."},{"key":"842_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393\u2013404.","journal-title":"Blood."},{"key":"842_CR33","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1182\/blood.V126.23.4025.4025","volume":"126","author":"A Hochhaus","year":"2015","unstructured":"Hochhaus A, Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, et al. Efficacy and safety of ponatinib in CP-CML patients by number of prior tyrosine kinase inhibitors: 4-year follow-up of the phase 2 PACE trial. Blood. 2015;126:4025.","journal-title":"Blood."},{"key":"842_CR34","volume-title":"Ponatinib 15 mg daily, combining efficacy and tolerability. A retrospective survey in Italy","author":"G Binotto","year":"2018","unstructured":"Binotto G, Castagnetti F, Gugliotta G, Abruzzese E, Iurlo A, Stagno F, et al. Ponatinib 15 mg daily, combining efficacy and tolerability. A retrospective survey in Italy. Stockholm: European Hematology Association; 2018."},{"key":"842_CR35","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1182\/blood.V128.22.3081.3081","volume":"128","author":"MJ Mauro","year":"2016","unstructured":"Mauro MJ, McGarry LJ, Lustgarten S, Huang H. Predictors of ponatinib therapy duration among real-world chronic phase chronic myeloid leukemia (CP-CML) patients in the US. Blood. 2016;128:3081.","journal-title":"Blood."},{"key":"842_CR36","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.clml.2016.07.086","volume":"16","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2016","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Cortes J, Deininger MW, Baer M, Kota VK, Akard L, et al. The OPTIC study: a multi-center, randomized phase 2 trial with response-based dose reduction to evaluate three starting doses of ponatinib. Clin Lymphoma Myeloma Leuk. 2016;16:S59\u201360.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"842_CR37","unstructured":"Activity and risk profile of ponatinib in chronic phase patients with chronic myeloid leukemia resistant to imatinib. https:\/\/ClinicalTrials.gov\/show\/NCT02398825."},{"key":"842_CR38","unstructured":"Ponatinib in participants with resistant chronic phase chronic myeloid leukemia (CP-CML) to characterize the efficacy and safety of a range of doses. https:\/\/ClinicalTrials.gov\/show\/NCT02467270."},{"key":"842_CR39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612\u201321.","journal-title":"Lancet Oncol."},{"key":"842_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","volume":"32","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev. 2018;32:289\u201399.","journal-title":"Blood Rev."},{"key":"842_CR41","doi-asserted-by":"publisher","unstructured":"Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020. https:\/\/doi.org\/10.1038\/s41375-020-0826-9.","DOI":"10.1038\/s41375-020-0826-9"},{"key":"842_CR42","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia."},{"key":"842_CR43","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0842-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0842-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0842-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:40:29Z","timestamp":1684618829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0842-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0842-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"9 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Members of the expert panel declare the following potential conflicts of interest: AH, Research support: BMS, Incyte, MSD, Novartis, Pfizer. Honoraria: BMS, Fusion Pharma, Incyte, Novartis, Pfizer, Takeda. MB, Honoraria: Celgene, Incyte, Novartis, Pfizer. GS, No financial relationship to disclose. VGG, Research support: BMS, Incyte, Novartis, Pfizer. Honoraria: BMS, Incyte, Novartis, Pfizer. DR, Honoraria: BMS, Novartis, Pfizer, Incyte. JJ, Research support: Novartis, BMS; Honoraria: Pfizer, Novartis, Incyte, Abbvie; Founder of Apps for Care and Science Foundation, developer of the HematologyApp. This non-profit organization is supported by Amgen, Sanofi-Genzyme, Takeda, Jazz, Roche, Servier, Celgene, Daiichi-Sankyo, Janssen, Incyte and BMS. JFA, Research support: Incyte, Novartis, Pfizer. Honoraria: BMS, Incyte, Novartis, Pfizer. None of the authors received an honorarium for this specific work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}